Hormonal

Chronic administration of a long-acting GLP-1/Glucagon receptor dual agonist (DualAG) causes superior weight loss and lipid lowering in diet-induced obese mice compared to a GLP-1 receptor selective agonist (GLPAG) of matched potency and pharmacokinetics.

This research suggests that combining GLP-1 and Glucagon receptor activation in a single long-acting molecule produces greater weight loss and better lipid profiles than activating the GLP-1 receptor alone. For obese individuals, this dual mechanism leverages both reduced food intake and increased energy expenditure/fatty acid oxidation. While this specific peptide (DualAG) is experimental, the findings support the clinical development of dual agonists (like retatrutide or similar candidates) as potentially more effective than current single-target GLP-1 therapies for obesity.